Before the era of tyrosine kinase inhibitors (TKIs), interferon-alpha (IFN-α) was the treatment of choice in chronic myeloid leukemia (CML). The gene discussed is IFNA1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.